Annual CFF
$71.70 M
-$57.90 M-44.67%
December 31, 2023
Summary
- As of February 7, 2025, MCRB annual cash flow from financing activities is $71.70 million, with the most recent change of -$57.90 million (-44.67%) on December 31, 2023.
- During the last 3 years, MCRB annual CFF has fallen by -$231.72 million (-76.37%).
- MCRB annual CFF is now -76.37% below its all-time high of $303.42 million, reached on December 31, 2020.
Performance
MCRB Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$110.87 M
-$110.87 M-100.00%
September 30, 2024
Summary
- As of February 7, 2025, MCRB quarterly cash flow from financing activities is -$110.87 million, with the most recent change of -$110.87 million (-100.00%) on September 30, 2024.
- Over the past year, MCRB quarterly CFF has dropped by -$117.30 million (-1824.55%).
- MCRB quarterly CFF is now -139.27% below its all-time high of $282.30 million, reached on September 30, 2020.
Performance
MCRB Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
-$85.68 M
-$112.31 M-421.69%
September 30, 2024
Summary
- As of February 7, 2025, MCRB TTM cash flow from financing activities is -$85.68 million, with the most recent change of -$112.31 million (-421.69%) on September 30, 2024.
- Over the past year, MCRB TTM CFF has dropped by -$157.38 million (-219.49%).
- MCRB TTM CFF is now -126.24% below its all-time high of $326.55 million, reached on September 30, 2020.
Performance
MCRB TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
MCRB Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -44.7% | -1824.5% | -219.5% |
| 3 y3 years | -76.4% | -2511.8% | -166.1% |
| 5 y5 years | +10000.0% | -2511.8% | -166.1% |
MCRB Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -44.7% | +5987.0% | -213.1% | at low | -151.5% | at low |
| 5 y | 5-year | -76.4% | +5987.0% | -139.3% | at low | -126.2% | at low |
| alltime | all time | -76.4% | >+9999.0% | -139.3% | at low | -126.2% | at low |
Seres Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$110.87 M(<-9900.0%) | -$85.68 M(-421.7%) |
| Jun 2024 | - | $0.00(-100.0%) | $26.63 M(-68.6%) |
| Mar 2024 | - | $18.76 M(+191.8%) | $84.81 M(+18.3%) |
| Dec 2023 | $71.70 M(-44.7%) | $6.43 M(+345.5%) | $71.70 M(+2.6%) |
| Sep 2023 | - | $1.44 M(-97.5%) | $69.87 M(-58.0%) |
| Jun 2023 | - | $58.18 M(+928.6%) | $166.46 M(+53.5%) |
| Mar 2023 | - | $5.66 M(+23.0%) | $108.41 M(-16.4%) |
| Dec 2022 | $129.60 M(>+9900.0%) | $4.60 M(-95.3%) | $129.60 M(+4.3%) |
| Sep 2022 | - | $98.03 M(>+9900.0%) | $124.22 M(+363.4%) |
| Jun 2022 | - | $130.00 K(-99.5%) | $26.81 M(-1.7%) |
| Mar 2022 | - | $26.85 M(-3542.1%) | $27.26 M(+2214.3%) |
| Dec 2021 | $1.18 M(-99.6%) | -$780.00 K(-228.1%) | $1.18 M(-70.1%) |
| Sep 2021 | - | $609.00 K(+4.1%) | $3.94 M(-98.6%) |
| Jun 2021 | - | $585.00 K(-23.4%) | $285.63 M(-4.7%) |
| Mar 2021 | - | $764.00 K(-61.5%) | $299.64 M(-1.2%) |
| Dec 2020 | $303.42 M(+251.9%) | $1.99 M(-99.3%) | $303.42 M(-7.1%) |
| Sep 2020 | - | $282.30 M(+1834.4%) | $326.55 M(+640.0%) |
| Jun 2020 | - | $14.59 M(+221.1%) | $44.13 M(-51.1%) |
| Mar 2020 | - | $4.54 M(-81.9%) | $90.30 M(+4.7%) |
| Dec 2019 | $86.23 M | $25.11 M(<-9900.0%) | $86.23 M(+41.0%) |
| Sep 2019 | - | -$118.00 K(-100.2%) | $61.17 M(-0.7%) |
| Jun 2019 | - | $60.76 M(>+9900.0%) | $61.58 M(+6645.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | $480.00 K(+966.7%) | $913.00 K(+240.7%) |
| Dec 2018 | $268.00 K(+222.9%) | $45.00 K(-84.9%) | $268.00 K(+35.4%) |
| Sep 2018 | - | $298.00 K(+231.1%) | $198.00 K(-807.1%) |
| Jun 2018 | - | $90.00 K(-154.5%) | -$28.00 K(-72.3%) |
| Mar 2018 | - | -$165.00 K(+560.0%) | -$101.00 K(-221.7%) |
| Dec 2017 | $83.00 K(-96.1%) | -$25.00 K(-134.7%) | $83.00 K(-23.1%) |
| Sep 2017 | - | $72.00 K(+323.5%) | $108.00 K(-91.2%) |
| Jun 2017 | - | $17.00 K(-10.5%) | $1.23 M(-38.5%) |
| Mar 2017 | - | $19.00 K(>+9900.0%) | $2.00 M(-6.5%) |
| Dec 2016 | $2.14 M(-98.4%) | $0.00(-100.0%) | $2.14 M(-0.1%) |
| Sep 2016 | - | $1.19 M(+51.7%) | $2.14 M(-98.5%) |
| Jun 2016 | - | $787.00 K(+401.3%) | $141.35 M(+1.5%) |
| Mar 2016 | - | $157.00 K(+7750.0%) | $139.21 M(+1.1%) |
| Dec 2015 | $137.72 M(+11.1%) | $2000.00(-100.0%) | $137.72 M(-44.8%) |
| Sep 2015 | - | $140.40 M(<-9900.0%) | $249.28 M(+128.2%) |
| Jun 2015 | - | -$1.35 M(+1.1%) | $109.26 M(-10.6%) |
| Mar 2015 | - | -$1.33 M(-101.2%) | $122.16 M(-1.5%) |
| Dec 2014 | $123.99 M(>+9900.0%) | $111.55 M(>+9900.0%) | $123.99 M(+896.9%) |
| Sep 2014 | - | $380.00 K(-96.7%) | $12.44 M(+3.2%) |
| Jun 2014 | - | $11.56 M(+2211.6%) | $12.06 M(+2311.6%) |
| Mar 2014 | - | $500.00 K | $500.00 K |
| Dec 2013 | $944.00 K(-90.0%) | - | - |
| Dec 2012 | $9.44 M | - | - |
FAQ
- What is Seres Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Seres Therapeutics?
- What is Seres Therapeutics annual CFF year-on-year change?
- What is Seres Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Seres Therapeutics?
- What is Seres Therapeutics quarterly CFF year-on-year change?
- What is Seres Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Seres Therapeutics?
- What is Seres Therapeutics TTM CFF year-on-year change?
What is Seres Therapeutics annual cash flow from financing activities?
The current annual CFF of MCRB is $71.70 M
What is the all time high annual CFF for Seres Therapeutics?
Seres Therapeutics all-time high annual cash flow from financing activities is $303.42 M
What is Seres Therapeutics annual CFF year-on-year change?
Over the past year, MCRB annual cash flow from financing activities has changed by -$57.90 M (-44.67%)
What is Seres Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of MCRB is -$110.87 M
What is the all time high quarterly CFF for Seres Therapeutics?
Seres Therapeutics all-time high quarterly cash flow from financing activities is $282.30 M
What is Seres Therapeutics quarterly CFF year-on-year change?
Over the past year, MCRB quarterly cash flow from financing activities has changed by -$117.30 M (-1824.55%)
What is Seres Therapeutics TTM cash flow from financing activities?
The current TTM CFF of MCRB is -$85.68 M
What is the all time high TTM CFF for Seres Therapeutics?
Seres Therapeutics all-time high TTM cash flow from financing activities is $326.55 M
What is Seres Therapeutics TTM CFF year-on-year change?
Over the past year, MCRB TTM cash flow from financing activities has changed by -$157.38 M (-219.49%)